查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837052

短腸症候群市場按治療類型、產品類型、給藥途徑、最終用途、患者年齡和病因分類－2025-2032 年全球預測

Short Bowel Syndrome Market by Treatment Type, Product Type, Route Of Administration, End Use, Patient Age, Etiology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，短腸症候群市場規模將成長至 41.1406 億美元，複合年成長率為 19.84%。

主要市場統計數據
基準年2024年 9.6642億美元
預計2025年 11.6059億美元
預測年份：2032年 4,114,060,000美元
複合年成長率（%） 19.84%

簡要概述影響腸衰竭患者護理的多方面臨床、後勤和治療動態

短腸症候群是一項複雜的多學科臨床挑戰，需要協調一致的護理模式、創新的治療方法以及靈活的供應鏈。患者的腸道功能受損程度各不相同，需要個別化地結合口服補液鹽、腸外營養、藥物治療，有時還需要手術介入。每種治療途徑都有不同的後勤需求和臨床終點，而最近的進展正在將重點從單純維持生命轉移到恢復生活品質並減少對腸外營養的長期依賴。

隨著向社區和居家護理的轉變持續推進，臨床團隊、支付方和製造商必須協調專科醫院干預措施與可擴展門診解決方案之間的矛盾。這種轉變凸顯了整合營養管理、藥物最佳化和手術決策的綜合護理計劃的重要性。此外，生物製藥和設備輔助手術的創新正在改變臨床對話，促使醫療系統重新評估臨床通訊協定、培訓需求和基礎設施投資。因此，相關人員必須以創新的方式，在治療效果、醫療服務物流和以病人為中心的治療結果之間尋求平衡。

治療創新、分散式醫療服務和供應鏈彈性如何重新定義短腸症候群管理

在治療方法創新、醫療分散化和監管預期不斷變化等因素的推動下，短腸症候群格局正在轉變。在治療方面，標靶藥物藥物的出現重新定義了治療目標，鼓勵臨床醫生進行腸道康復，減少對腸外營養的依賴，而不是無限期地依賴支持性治療。外科手術創新不斷推進，腸道延長手術更加複雜，移植途徑更加協調，這些都為患者拓展了治療選擇，並挑戰了傳統的治療流程。

同時，長期營養照護朝向居家和門診環境的轉變，促使人們更加重視可靠的供應鏈、病患訓練和遠端監控能力。遠端醫療支援的臨床追蹤和數位依從性工具正成為護理計畫不可或缺的一部分，從而能夠更早進行干預並更有效率地利用資源。從市場角度來看，製造商和服務供應商正在推出差異化的產品系列，將營養配方、輔助性治療和設備支援相結合。因此，競爭優勢取決於跨職能部門的編配，將臨床效益與可擴展的交付模式和強大的支援服務相結合。

評估近期關稅行動對短腸症候群生態系統的供應安全、臨床連續性和商業策略的連鎖反應

對進口醫療用品和原料徵收新關稅，給整個短腸症候群護理生態系統帶來了明顯的壓力，影響了製造商、經銷商和供應商。胺基酸混合物、脂肪乳劑和專用腸內配方等關鍵成分的供應鏈遍布複雜的全球網路。對這些投入品徵收關稅增加了採購的複雜性，迫使製造商重新評估籌資策略。為此，企業正在多元化其供應商基礎，增加庫存緩衝，並在可能的情況下轉向國產投入品，以減少國際貿易摩擦的風險。

然而，這些調整會對下游產生影響。醫院和家庭輸液服務提供者必須在採購的波動性與臨床對穩定產品供應的需求之間取得平衡，這需要與供應商密切合作並嚴格審查緊急時應對計畫。臨床醫生可能會觀察到產品替代和配方可用性方面存在更大的差異，需要謹慎管理以保持臨床的連續性。此外，關稅可能會增加進口臨床實驗藥物和醫療設備組件的直接成本，從而影響臨床試驗和商業上市的經濟效益，並可能延遲申辦方的決策並延長上市時間。

製造商優先考慮供應鏈的彈性和成本效率，服務供應商正在投資物流能力和供應商夥伴關係，而臨床網路則在採購受限的情況下優先考慮醫療服務的連續性。這些轉變凸顯了主動的貿易風險管理和協作合約架構對於保障病患獲得醫療服務並維持醫療服務的一致性的重要性。

全面剖析決定短腸症候群治療需求和商業性定位的臨床、產品、途徑、環境、年齡和病因部分

了解細分的細微差別，可以揭示臨床需求、產品設計和護理環境如何交織，共同塑造競爭和臨床路徑。在分析治療類型時，我們會關注口服補充劑、腸外營養、藥物治療和外科干預，並將口服補充劑細分為營養補充劑和營養配方，腸外營養細分為定製配方和標準化配方，藥物治療細分為抗生素、生長因子和激素，外科干預細分為腸移植和腸道延長手術。這種基於治療的細分凸顯了不同的需求促進因素，有些患者依賴藥物來增強吸收，有些患者需要透過定製或標準化解決方案獲得長期腸外支持，還有一部分患者需要手術復原。

按產品類型分類，市場包括輔助性治療、腸外營養、藥物製劑和腸外營養解決方案。輔助性治療也包括益生菌、維生素和礦物質；腸內製劑分為元素製劑、聚合物製劑和半元素製劑；藥物製劑以替度魯肽等藥物為主；腸外營養包括胺基酸溶液、碳水化合物溶液和脂肪乳化。該產品特定圖譜突顯了臨床差異化、製劑科學和監管途徑的交匯點，展現了製劑最佳化和支持性護理商品搭售的機會。

給藥途徑是另一個關鍵維度，靜脈注射和口服給藥決定了設備需求、病患教育要求和監測強度。居家照護強調培訓、遠端監控和物流；醫院優先考慮急性護理和複雜的外科手術；專科診所強調多學科復健和長期追蹤。將患者年齡分層為成人、老年和兒童組可以揭示不同的生理需求、劑量和看護者動態，而基於病因的細分（先天性疾病、克隆氏症、腸系膜缺血）則顯示出疾病軌跡和治療意圖的異質性。這些相交的細分框架為產品設計、臨床試驗人群、報銷策略和通路開發提供資訊，使相關人員能夠將投資組合策略與精確的臨床和營運要求相結合。

醫療保健基礎設施、報銷環境和醫療保健提供者能力的地區差異如何影響全球短腸症候群市場的准入和採用

全球短腸症候群市場的區域動態顯著影響著臨床實務模式、監管格局和商業策略。在美洲，完善的家庭輸液基礎設施和成熟的報銷途徑支持先進的營養療法，並促進了藥物在腸道復健中的應用。該地區的相關人員正優先考慮與慢性病照護模式的整合，並增加對病患教育和遠端監控的投資，以減少對醫院的依賴並改善長期療效。

歐洲、中東和非洲各地的醫療體系提供先進治療藥物和專科外科服務的可近性水準參差不齊，因此需要採取差異化的市場策略。雖然重症監護仍然是該地區多個市場複雜干預措施的主導模式，但人們對門診病人營養管理日益成長的興趣為基於社區的生產和客製化的經銷夥伴提供了機會。不同的政策和監管差異需要製定細緻的打入市場策略，以適應每個國家的報銷框架和臨床指南。

亞太地區醫療基礎設施發展迅速，但人口結構差異較大，既帶來了挑戰，也帶來了機會。該地區的都市區擴大採用先進的藥物和外科解決方案，而資源受限的環境則優先考慮擴充性的腸內和腸外治療策略。製造商和服務供應商的成功取決於靈活的產品系列、與本地經銷商的合作夥伴關係關係，以及對臨床醫生教育的投資，以彌合醫療服務提供方面的差距，並擴大不同醫療保健體系之間的醫療服務可及性。

了解策略夥伴關係、配方專業化和綜合護理能力如何決定短腸症候群的競爭優勢

短腸症候群領域的競爭態勢體現了大型製藥企業和營養公司、特殊生物製藥開發商以及管理複雜輸液和居家照護服務的服務供應商的混合格局。主要企業專注於透過投資專有配方、以臨床醫生為中心的教育計畫以及確保關鍵腸外和腸內產品一致性的供應鏈來打造明顯的差異化。同時，專業的創新者則透過開發針對腸道適應症的標靶藥物配方或與臨床中心合作以產生改變實踐的證據來追求利基優勢。

戰略夥伴關係已成為加速市場進入和擴大規模的熱門途徑。透過匯集配方和物流專家，他們可以彌合產品創新與可靠的現場交付之間的差距。此外，企業正增加對數位護理平台的投資，這些平台透過實現遠端患者監護、依從性追蹤、簡化輸液管理等功能，與其核心產品形成互補。產品、服務和數位工具的融合創造了一種競爭格局，支付方和醫療服務提供者都在尋求能夠減輕看護者負擔並顯著改善患者治療效果的綜合解決方案。企業必須在研發投資與製造彈性、法規遵循以及向不同相關人員傳達價值等務實考量之間取得平衡。

製造商、醫療保健提供者和付款人的策略和營運重點是保護患者的治療機會並加快治療結果

產業領導者應將短期營運改善與長期策略投資結合，以鞏固自身地位並改善病患治療效果。首先，優先考慮供應鏈多元化和關鍵投入（例如胺基酸、脂肪乳劑和特殊腸內成分）的雙重採購，以降低關稅和貿易風險，並支持不間斷的臨床交付。同時，投資強大的居家照護支援項目，包括標準化培訓課程、遠端監控技術和藥劑師主導的藥物管理，以提高住院過渡期間的安全性和依從性。

其次，我們將專注於研發能夠引起支付方和醫療服務提供者共鳴的臨床終點，透過收集減少腸外依賴、降低住院率以及患者報告生活品質的證據。在可能的情況下，我們將進行務實的研究和現實世界證據舉措，以證明跨病因和跨年齡層的多學科治療方法的有效性。第三，我們將與專科診所和多學科中心建立夥伴關係，簡化可能受益於手術方案、生長因子和腸道復健服務的患者治療途徑，並確保最佳化轉診網路和護理協調機制。

最後，發展靈活的商業模式，解決當地的報銷現實問題，並支援捆綁契約，以實現綜合服務和產品交付。透過結合營運彈性、循證開發、臨床夥伴關係和適應性強的市場開發方法，領導者可以提供更可預測和改進的病人歷程，同時保持競爭優勢。

結合臨床醫生參與、文獻綜合和營運審查的嚴格多方法研究途徑檢驗了臨床和商業性見解

調查方法採用多方法論，將初步質性研究與嚴謹的二次分析結合，以整體情況短腸症候群。主要方法包括與胃腸病學、外科、營養學和家庭輸液服務領域的臨床醫生進行深入訪談，以及與供應鏈經理和付款人代表進行結構化諮詢，以了解營運限制和報銷促進因素。此外，還與關鍵意見領袖舉行了顧問小組會議，以檢驗臨床路徑並確定不同患者群體中未滿足的需求。

二級資訊來源包括同行評審的臨床文獻、監管通知、臨床試驗註冊中心和公共衛生指南，以繪製治療機制、安全性概況和護理實踐標準。此外，還分析了產品標籤、生產指南文件和通路，以評估配方的複雜性和物流要求。數據品質程序包括跨多個資訊來源的三角測量、與臨床指南的一致性以及與臨床專家的迭代檢驗，以確保結論反映當前的實踐和營運現狀。在整個過程中，我們將見解按治療類型、產品類別、給藥途徑、護理環境、患者年齡和疾病病因進行分類，以保持分析的精細度和實際相關性。

專注於臨床創新、營運彈性和夥伴關係關係的策略整合將決定未來的有效性和可近性

短腸症候群既帶來了持續的挑戰，也帶來了新的機遇，需要臨床醫生、製造商、付款者和服務提供者的協調應對。藥物和外科技術的進步擴大了治療的可能性，而向家庭營養管理的轉變則需要加強物流、病患教育和遠端監控。貿易政策的變化和供應鏈中斷進一步加劇了環境的複雜性，迫使各組織優先考慮具有韌性和適應性的籌資策略。

未來的永續發展將取決於將證據生成與以患者為中心的實用交付模式相結合。相關人員若能將臨床創新與卓越營運相結合，在整個醫療照護過程中建立夥伴關係，並向付款人傳達清晰的價值提案，將最有可能改善患者軌跡並創造永續的商業性優勢。在此背景下，將臨床細節與醫療服務實際結合的可操作情報將成為策略決策和有效專案執行的關鍵輸入。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 類升糖素樣胜肽-2類似物療法的出現擴大了短腸症候群的治療選擇
  • 腸道延長手術技術的進步改善了成年患者的預後
  • 擴大居家腸外營養系統的採用可改善 SBS 患者的生活品質
  • 再生醫學和組織工程中修復腸黏膜的新方法
  • 整合遠端醫療服務進行營養管理，改善病患監測與遵從性
  • 人們對微生物組調節療法的興趣日益濃厚，以減少併發症並支持腸道適應
  • 不斷變化的報銷和定價策略正在影響整個全部區域獲得專業 SBS 護理的機會

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章短腸症候群市場（依治療類型）

  • 口服補充劑
    • 營養補充品
    • 營養配方
  • 靜脈營養
    • 客製化PN
    • 標準 PN
  • 藥物治療
    • 抗生素
    • 生長因子
    • 荷爾蒙
  • 外科手術干預
    • 腸道移植
    • 腸道延長手術

第9章短腸症候群市場（依產品類型）

  • 輔助性治療
    • 益生菌
    • 維生素和礦物質
  • 經腸營養
    • 元素膳食補充劑
    • 消化營養補充品
    • 半消化營養補充品
  • 藥理
    • 替度魯肽
  • PN解決方案
    • 胺基酸溶液
    • 碳水化合物解決方案
    • 脂肪乳劑

短腸症候群市場（依給藥途徑）

  • 靜脈
  • 口服

第 11 章短腸症候群市場：依最終用途

  • 居家護理設施
  • 醫院
  • 專科診所

第 12 章短腸症候群市場（依病患年齡）

  • 成人
  • 老年人
  • 孩子們

第13章短腸症候群市場：依病因

  • 先天性疾病
  • 克隆氏症
  • 腸繫膜缺血

第14章短腸症候群市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章短腸症候群市場：按組

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章短腸症候群市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Ajinomoto Co., Inc.
    • Terumo Corporation
    • Becton, Dickinson and Company
    • ICU Medical, Inc.
    • Smiths Medical（Smiths Group plc）
    • Otsuka Holdings Co., Ltd.
    • Lonza Group AG
    • CordenPharma International AG
    • Gland Pharma Limited
    • Hikma Pharmaceuticals PLC
Product Code: MRR-0309FBC51139

The Short Bowel Syndrome Market is projected to grow by USD 4,114.06 million at a CAGR of 19.84% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 966.42 million
Estimated Year [2025] USD 1,160.59 million
Forecast Year [2032] USD 4,114.06 million
CAGR (%) 19.84%

A concise overview of the multifaceted clinical, logistical, and therapeutic dynamics reshaping care for patients with intestinal failure

Short bowel syndrome represents a complex, multidisciplinary clinical challenge that demands coordinated care models, innovative therapeutics, and adaptive supply chains. Patients experience variable intestinal function losses that necessitate individualized combinations of oral supplementation, parenteral nutrition, pharmacological therapy, and sometimes surgical intervention. Each therapeutic pathway carries distinct logistical requirements and clinical endpoints, and recent advances have shifted the emphasis from merely sustaining life to restoring quality of life and reducing long-term dependence on parenteral support.

As care moves increasingly into community and home settings, clinical teams, payers, and manufacturers must reconcile the tension between specialized hospital-based interventions and scalable outpatient solutions. This dynamic elevates the importance of integrated care plans that connect nutritional management, pharmacologic optimization, and surgical decision-making. Moreover, innovations in biological agents and device-assisted procedures are altering the clinical conversation, prompting health systems to reassess clinical protocols, training needs, and infrastructure investments. Consequently, stakeholders must navigate a landscape where therapeutic efficacy, delivery logistics, and patient-centered outcomes intersect in novel ways.

How innovation in therapeutics, decentralization of care delivery, and supply chain resilience are collectively redefining short bowel syndrome management

The short bowel syndrome landscape is undergoing transformative shifts driven by therapeutic innovation, decentralization of care, and evolving regulatory expectations. On the therapeutic front, the emergence of targeted pharmacologic agents has redefined treatment goals, encouraging clinicians to pursue intestinal rehabilitation and reduction of parenteral dependence rather than indefinite support. Surgical innovation continues to progress with refined intestinal lengthening techniques and more coordinated transplant pathways, which collectively expand patient options and challenge traditional care algorithms.

Simultaneously, the migration of long-term nutritional management into the home and outpatient settings has intensified focus on reliable supply chains, patient training, and remote monitoring capabilities. Telehealth-enabled clinical follow-up and digital adherence tools are becoming integral to care plans, enabling earlier interventions and more efficient resource utilization. From a market perspective, manufacturers and service providers are responding with differentiated product portfolios that combine nutritional formulations, adjunctive therapies, and device-enabled support, while payers increasingly demand evidence of real-world outcomes and cost-effectiveness. As a result, competitive advantage now hinges on cross-functional orchestration that aligns clinical benefit with scalable delivery models and robust support services.

Evaluating the ripple effects of recent tariff actions on supply security, clinical continuity, and commercial strategies within the short bowel syndrome ecosystem

The imposition of new tariffs on imported medical goods and raw materials has created palpable stress across the short bowel syndrome care ecosystem, affecting manufacturers, distributors, and providers. Supply lines for critical components such as amino acid blends, lipid emulsions, and specialized enteral formulas traverse complex global networks; tariffs on these inputs increase procurement complexity and compel manufacturers to reassess sourcing strategies. In response, organizations are diversifying supplier bases, increasing inventory buffers, and, where feasible, shifting toward domestically produced inputs to reduce exposure to international trade friction.

These adjustments, however, carry downstream effects. Hospitals and home infusion providers must reconcile procurement variability with the clinical necessity for consistent product availability, prompting closer collaboration with suppliers and heightened scrutiny of contingency planning. Clinicians may observe greater variability in product substitution and formulation availability, requiring careful management to preserve clinical continuity. Moreover, tariffs influence the economics of clinical trials and commercial launches by raising the direct cost of imported investigational materials and device components, which can slow sponsor decision-making and extend timelines for market entry.

In aggregate, the tariff environment accelerates strategic realignment across the value chain: manufacturers prioritize supply chain resilience and cost-efficiency, service providers invest in logistics capabilities and supplier partnerships, and clinical networks emphasize therapeutic continuity under constrained procurement conditions. These shifts underscore the importance of proactive trade-risk management and collaborative contracting frameworks to safeguard patient access and maintain therapeutic consistency.

A comprehensive dissection of clinical, product, route, setting, age, and etiology segments that determines therapeutic needs and commercial positioning for short bowel syndrome

A nuanced understanding of segmentation reveals how clinical need, product design, and care settings intersect to shape competition and clinical pathways. When analyzing treatment type, the landscape spans oral supplementation, parenteral nutrition, pharmacological therapy, and surgical intervention, where oral supplementation subdivides into dietary supplements and nutritional formulas, parenteral nutrition distinguishes customized and standard formulations, pharmacological therapy separates into antibiotics, growth factors, and hormonal agents, and surgical intervention includes bowel transplantation and intestinal lengthening procedures. This treatment-based segmentation highlights distinct demand drivers: some patients rely on pharmacologic agents to enhance absorptive capacity, others require long-term parenteral support with either bespoke or standardized solutions, and a subset proceed to surgical restoration efforts.

Looking through the lens of product type, the market encompasses adjunctive therapies, enteral formulas, pharmacologics, and parenteral nutrition solutions. Adjunctive therapies further include probiotics and vitamins and minerals, while enteral formulas are differentiated into elemental, polymeric, and semi-elemental variants; pharmacologics center on agents such as teduglutide, and parenteral solutions cover amino acid solutions, carbohydrate solutions, and lipid emulsions. This product-focused map clarifies where clinical differentiation, formulation science, and regulatory pathways converge, signaling opportunities for formulation optimization and supportive therapy bundling.

Route of administration provides another critical axis, with intravenous and oral pathways dictating device needs, patient education requirements, and monitoring intensity. End-use segmentation across home care facilities, hospitals, and specialty clinics underscores the operational implications of each treatment pathway: home care emphasizes training, remote monitoring, and logistics; hospitals prioritize acute management and complex surgical interventions; specialty clinics focus on multidisciplinary rehabilitation and longitudinal follow-up. Patient age stratification into adult, geriatric, and pediatric cohorts reveals differing physiologic needs, dosing considerations, and caregiver dynamics, while etiology-based segments-congenital conditions, Crohn disease, and mesenteric ischemia-demonstrate heterogeneity in disease trajectory and therapeutic intent. Together, these intersecting segmentation frameworks inform product design, clinical trial populations, reimbursement strategies, and channel development, enabling stakeholders to align portfolio strategies with precise clinical and operational requirements.

How distinct regional healthcare infrastructures, reimbursement environments, and provider capabilities shape access and adoption across global short bowel syndrome markets

Regional dynamics exert a powerful influence on clinical practice patterns, regulatory expectations, and commercial strategies across the global short bowel syndrome landscape. In the Americas, established home infusion infrastructures and mature reimbursement pathways support advanced nutritional therapies and facilitate adoption of pharmacologic agents aimed at intestinal rehabilitation. Stakeholders in this region emphasize integration with chronic care models and investment in patient education and remote monitoring to reduce hospital reliance and improve long-term outcomes.

Across Europe, the Middle East & Africa, health systems exhibit varied levels of access to advanced therapeutics and specialized surgical services, necessitating differentiated market approaches. In several markets within this region, centralized hospital care remains the dominant model for complex interventions, while growing interest in outpatient nutritional management presents opportunities for localized manufacturing and tailored distribution partnerships. Policy heterogeneity and regulatory divergence require nuanced market access strategies that accommodate national reimbursement frameworks and clinical guidelines.

The Asia-Pacific region combines rapidly developing healthcare infrastructure with high population heterogeneity, creating both challenges and opportunities. Urban centers in this region increasingly adopt advanced pharmacologic and surgical solutions, while resource-constrained settings prioritize scalable enteral and parenteral strategies. For manufacturers and service providers, success depends on flexible product portfolios, collaborative partnerships with local distributors, and investments in clinician education to bridge gaps in care delivery and expand appropriate access across diverse healthcare systems.

Insights into how strategic partnerships, formulation specialization, and integrated care capabilities determine competitive advantage in short bowel syndrome

Competitive dynamics in the short bowel syndrome domain reflect a blend of large pharmaceutical and nutrition firms, specialty biologic developers, and service providers that manage complex infusion and home care delivery. Leading companies concentrate on charting clear differentiation through proprietary formulations, clinician-focused education programs, and supply chain investments that ensure consistency of critical parenteral and enteral products. At the same time, specialized innovators pursue niche advantages by developing targeted pharmacologics that address intestinal adaptation and by partnering with clinical centers to generate practice-changing evidence.

Strategic partnerships have become a common pathway to accelerate market entry and scale; collaborations between formulation experts and logistics specialists help bridge gaps between product innovation and reliable in-field delivery. Additionally, a growing number of companies are investing in digital care platforms that complement core products, enabling remote patient monitoring, adherence tracking, and streamlined infusion management. This convergence of product, service, and digital tools fosters a competitive environment where integrated solutions that reduce caregiver burden and demonstrably improve patient outcomes command attention from payers and providers alike. To remain relevant, companies must balance investments in R&D with pragmatic attention to manufacturing resilience, regulatory navigation, and value communication to diverse stakeholders.

Actionable strategic and operational priorities that manufacturers, providers, and payers should implement to safeguard access and accelerate therapeutic impact for patients

Industry leaders should pursue a mix of immediate operational improvements and longer-term strategic investments to strengthen position and enhance patient outcomes. First, prioritize supply chain diversification and dual sourcing for critical inputs such as amino acids, lipid emulsions, and specialized enteral components to reduce tariff and trade exposure and to support uninterrupted clinical delivery. Concurrently, invest in robust home care enablement programs that include standardized training curricula, remote monitoring technologies, and pharmacist-led medication management to improve safety and adherence as care shifts away from inpatient settings.

Second, align R&D focus with clinical endpoints that resonate with payers and providers by generating evidence on reduced parenteral dependence, hospital readmissions, and patient-reported quality of life. Where possible, pursue pragmatic studies and real-world evidence initiatives that demonstrate the effectiveness of combined therapeutic approaches across different patient etiologies and age groups. Third, cultivate partnerships with specialty clinics and multidisciplinary centers to streamline pathways for patients who may benefit from surgical options, growth factors, or intestinal rehabilitation services, ensuring that referral networks and care coordination mechanisms are optimized.

Lastly, develop flexible commercial models that accommodate regional reimbursement realities and support bundled contracting for integrated service-product offerings. By combining operational resilience, evidence-driven development, clinical partnerships, and adaptable go-to-market approaches, leaders can sustain competitive advantage while delivering more predictable and improved patient journeys.

A rigorous multimethod research approach combining clinician engagement, literature synthesis, and operational review to validate clinical and commercial insights

The research methodology employed a multimodal approach that synthesizes primary qualitative insight with rigorous secondary analysis to develop a holistic view of the short bowel syndrome landscape. Primary methods included in-depth interviews with clinicians across gastroenterology, surgery, nutrition, and home infusion services, as well as structured consultations with supply chain managers and payer representatives to understand operational constraints and reimbursement drivers. These conversations were complemented by advisory-panel sessions with key opinion leaders to validate clinical pathways and identify unmet needs across different patient cohorts.

Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, clinical trial registries, and public health guidance to map therapeutic mechanisms, safety profiles, and standard-of-care practices. Additionally, product labeling, manufacturing guidance documents, and distribution channel analyses informed assessments of formulation complexity and logistical requirements. Data quality procedures included triangulation across multiple sources, consistency checks against clinical guidelines, and iterative validation with clinical experts to ensure that conclusions reflect current practice and operational realities. Throughout the process, care was taken to disaggregate insights across treatment types, product classes, routes of administration, care settings, patient ages, and etiologies to preserve analytical granularity and practical relevance.

A strategic synthesis of clinical innovation, operational resilience, and partnership-focused strategies that will determine future efficacy and access

Short bowel syndrome presents both persistent challenges and emerging opportunities that require coordinated responses from clinicians, manufacturers, payers, and service providers. Advances in pharmacologic agents and surgical techniques expand therapeutic possibilities, while the shift toward home-based nutritional management demands strengthened logistics, patient education, and remote monitoring. Trade policy changes and supply chain disruptions further complicate the environment, prompting organizations to prioritize resilience and adaptable sourcing strategies.

Moving forward, sustainable progress will depend on the ability to integrate evidence generation with practical delivery models that prioritize patient-centered outcomes. Stakeholders that align clinical innovation with operational excellence, cultivate partnerships across the care continuum, and communicate clear value propositions to payers will be best positioned to improve patient trajectories and create durable commercial advantage. In this context, actionable intelligence that bridges clinical nuance and real-world delivery mechanics becomes an essential input for strategic decision-making and effective program execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging glucagon-like peptide-2 analog therapies expanding treatment options for short bowel syndrome
  • 5.2. Advancements in intestinal lengthening surgical techniques improving patient outcomes in adults
  • 5.3. Growing adoption of home parenteral nutrition delivery systems enhancing quality of life in SBS patients
  • 5.4. Emerging regenerative medicine and tissue engineering approaches targeting intestinal mucosa restoration
  • 5.5. Integration of telehealth services for nutritional management improving patient monitoring and adherence
  • 5.6. Increasing focus on microbiome modulation therapies to reduce complications and support intestinal adaptation
  • 5.7. Evolving reimbursement and pricing strategies impacting access to specialized SBS treatments across regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Short Bowel Syndrome Market, by Treatment Type

  • 8.1. Oral Supplementation
    • 8.1.1. Dietary Supplements
    • 8.1.2. Nutritional Formulas
  • 8.2. Parenteral Nutrition
    • 8.2.1. Customized Pn
    • 8.2.2. Standard Pn
  • 8.3. Pharmacological Therapy
    • 8.3.1. Antibiotics
    • 8.3.2. Growth Factors
    • 8.3.3. Hormonal Agents
  • 8.4. Surgical Intervention
    • 8.4.1. Bowel Transplantation
    • 8.4.2. Intestinal Lengthening Procedures

9. Short Bowel Syndrome Market, by Product Type

  • 9.1. Adjunctive Therapies
    • 9.1.1. Probiotics
    • 9.1.2. Vitamins And Minerals
  • 9.2. Enteral Formulas
    • 9.2.1. Elemental Formulas
    • 9.2.2. Polymeric Formulas
    • 9.2.3. Semi-elemental Formulas
  • 9.3. Pharmacologics
    • 9.3.1. Teduglutide
  • 9.4. Pn Solutions
    • 9.4.1. Amino Acid Solutions
    • 9.4.2. Carbohydrate Solutions
    • 9.4.3. Lipid Emulsions

10. Short Bowel Syndrome Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Short Bowel Syndrome Market, by End Use

  • 11.1. Home Care Facilities
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Short Bowel Syndrome Market, by Patient Age

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Short Bowel Syndrome Market, by Etiology

  • 13.1. Congenital Conditions
  • 13.2. Crohn Disease
  • 13.3. Mesenteric Ischemia

14. Short Bowel Syndrome Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Short Bowel Syndrome Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Short Bowel Syndrome Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Ajinomoto Co., Inc.
    • 17.3.2. Terumo Corporation
    • 17.3.3. Becton, Dickinson and Company
    • 17.3.4. ICU Medical, Inc.
    • 17.3.5. Smiths Medical (Smiths Group plc)
    • 17.3.6. Otsuka Holdings Co., Ltd.
    • 17.3.7. Lonza Group AG
    • 17.3.8. CordenPharma International AG
    • 17.3.9. Gland Pharma Limited
    • 17.3.10. Hikma Pharmaceuticals PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA SHORT BOWEL SYNDROME MAR